Trastuzumab

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

Retrieved on: 
木曜日, 5月 23, 2024
MSD, Pembrolizumab, Merck & Co., Patient, Oxidative stress, TPS, Trastuzumab, Science, HER2, Proteostasis, Tumor microenvironment, FDA, Endometrial cancer, Safety, Breast cancer, ADC, Senior, Headquarters, LEAP, Research, Deep, Cancer, Drug discovery, ASCO, Merck, PRISM, Society, Apoptosis, Hepatocellular carcinoma, Differentiable function, Inflammation, Hypoxia, Annual general meeting, Pharmaceutical industry

TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.

Key Points: 
  • TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains with the aim of contributing to the cure of cancers.
  • (1) KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Fosun Sells German Private Bank HAL and Retains HAFS Asset Servicing Business, Aligns with its Asset-Light Strategy

Retrieved on: 
火曜日, 5月 28, 2024
FTG, HKEX, Trastuzumab, S&P, Happiness, UBS, Ecosystem, Sale, Club Med, Marketing, IRR, Fosun Pharma, Complementarity, HAL, Overweight, Growth, ABN AMRO, ABN, Citibank, Face, AMRO Bank, Acquisition, Cell, Gene, HAFS, Tourism, Bank

HAFS is one of the ten major asset servicing companies in German-speaking regions.

Key Points: 
  • HAFS is one of the ten major asset servicing companies in German-speaking regions.
  • The announcement indicates that the sale is part of Fosun's ongoing efforts to optimize its asset portfolio and focus on asset-light operations.
  • It is worth noting that based on the transaction consideration of EUR670.3 million, the project is expected to yield double-digit IRR for Fosun.
  • Fosun International will continue to hold the asset servicing business, which is an asset-light "cash cow" operation.

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Retrieved on: 
火曜日, 5月 14, 2024
Acute leukemia, Patient, Pharmacokinetics, CML, Investigational New Drug, Trastuzumab, Food, MBC, HER2, Colorectal cancer, Therapy, BCR, MBA, MD, Cancer, PIPE, CRC, MMR, Research, Central nervous system, G&A, Tucatinib, Food and Drug Administration, Brain, Pharmaceutical industry

BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the first quarter ended March 31, 2024, and provided a business update, including highlights of pipeline progress.

Key Points: 
  • “The first quarter of 2024 was a pivotal quarter for Enliven.
  • Research and development (R&D) expenses: R&D expenses were $20.0 million for the first quarter of 2024, compared to $11.9 million for the first quarter of 2023.
  • General and administrative (G&A) expenses: G&A expenses for the first quarter of 2024 were $6.0 million, compared to $4.5 million for the first quarter of 2023.
  • Net Loss: Enliven reported a net loss of $22.7 million for the first quarter of 2024, compared to a net loss of $14.7 million for the first quarter of 2023.

REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer

Retrieved on: 
火曜日, 5月 14, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Patient, Trastuzumab, Toxicity, Risk, Level 1, HER2, Breast cancer, Radiation, Neoadjuvant therapy, PCR, Research, Taxane, Medicine, THP, Multimedia, Quality of life, Pertuzumab, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240509117263/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240509117263/en/
    The CompassHER2 pCR Trial (also EA1181) is a single-arm phase II neoadjuvant study that successfully enrolled 2175 patients with stage II or IIIa HER2-positive (HER2+) breast cancer.
  • In this collaboration, the CompassHER2 pCR Trial protocol has been amended to include the evaluation of the HER2DX® genomic test as a key secondary correlative endpoint.
  • REVEAL GENOMICS' CEO, Patricia Villagrasa, added, "The inclusion of HER2DX® in the CompassHER2 pCR Trial is a testament to our commitment to advancing breast cancer treatment.
  • This pivotal collaboration represents a significant step towards personalized medicine in the management of early-stage HER2-positive breast cancer.

Kexing Biopharm Teams Up with Qingfeng Pharma for the Global Market on Olaparib Tablets

Retrieved on: 
金曜日, 5月 10, 2024
USD, Cancer, NCCN, Trastuzumab, Tablet, GC, PARP, Pancreatic cancer, Breast cancer, Prostate cancer, BRCA, Eribulin, Malignancy, Marketing, GMP, Paclitaxel, EPO, Ovarian cancer, Birth control

Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a subsidiary of Qingfeng Pharmaceutical Group (hereinafter referred to as "Qingfeng Pharma"), for the international commercialization of Olaparib Tablets.

Key Points: 
  • Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a subsidiary of Qingfeng Pharmaceutical Group (hereinafter referred to as "Qingfeng Pharma"), for the international commercialization of Olaparib Tablets.
  • The agreement grants Kexing Biopharm the rights to commercialize Qingfeng Pharma-manufactured Olaparib Tablets in 10 oversea countries.
  • Since the beginning of 2024, Kexing Biopharm has received numerous on-site GMP inspections by health authorities from various oversea countries.
  • As the company licenses in more new products, its global presence will continue to grow, and mark a bright future.

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Investment, Risk, Destiny, IND, Autoimmune disease, Enrollment, Death, Hospital, GAAP, NK, GEJ, Multiple myeloma, CRS, HER2, Pharmacokinetics, Graft-versus-host disease, Food, Lupus, Data, ADR, BCL, Histology, Therapy, BCMA, Autoimmunity, Safety, Trastuzumab, Research, TRAC, Incidence, IPSC, Chronic lymphocytic leukemia, Acute leukemia, Investigational New Drug, Cancer, Cell, Cmax, Patient, Gene, Society, B-cell lymphoma, BCM, Cytokine release syndrome, Immune system, SLE, Vaccine

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The patient was discharged after a three-day hospital stay without any notable adverse events.
  • The Company will conduct a conference call today, Thursday, May 9, 2024 at 5:00 p.m.
  • ET to review financial and operating results for the quarter and full year ended March 31, 2024.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.

Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

Retrieved on: 
水曜日, 5月 8, 2024
MSD, PFS, FDA, Pfizer, MRNA, News, Atrophy, Weight loss, Doctor of Philosophy, Vaccine, University of Toronto, PFE, Medicinal chemistry, Medicine, Genome, Moderna, Diagnosis, AstraZeneca, Prevalence, GEJ, University, CPS, HER2, Food, OTC, IHC, Cachexia, Pneumococcal conjugate vaccine, Messenger, Quality of life, RSV, Patient, Facial muscles, Professor, Oncology, Trastuzumab, Research, Incidence, Fatigue, EPS, Neoplasm, MUSL, MRK, Tafamidis, Progression-free survival, PALM, PD-L1, COVID-19, Growth, Pharmaceutical industry

Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.

Key Points: 
  • Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.
  • The Cancer Cachexia market refers to the segment of the healthcare industry focused on addressing the multifaceted challenges associated with cachexia in cancer patients.
  • A report from Custom Market Insights projects that the global Cancer Cachexia Market is expected to record a CAGR of 5.1% from 2024 to 2033.
  • In 2024, the market size is projected to reach a valuation of USD 3.3 Billion.

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 2, 2024
Transfer, Breast cancer, FDA, The Transfer Agreement, Food, BTC, Research, Trastuzumab, MAA, Insurance, Jazz Pharmaceuticals, MSAT, Abstract, IND, ASCO, Disease, CD28, HER2, Tax, ADC, Three Months, Patient, Society, EMA, Bone marrow, BLA, Standard of care, AACR, Autoimmunity, European Medicines Agency, Pharmaceutical industry

In May 2024, our partner Jazz guided that their plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC are proceeding.

Key Points: 
  • In May 2024, our partner Jazz guided that their plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC are proceeding.
  • Financial Results for the Three Months Ended March 31, 2024
    Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.
  • Other income, net increased by $1.9 million for the three months ended March 31, 2024 compared to the same period in 2023.
  • Net loss for the three months ended March 31, 2024 was $31.7 million compared to $24.4 million loss for the same period in 2023.

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Retrieved on: 
水曜日, 5月 1, 2024
Biotechnology, General Health, Pharmaceutical, Health, MSD, PFS, CPS, FDA, Congress, HER2, Food, Oncology, Merck & Co., Progression-free survival, Pembrolizumab, Survival, Trastuzumab, ESMO, OS, PD-L1, Patient, Neoplasm, ITT, MRK, GEJ, Pharmaceutical industry

Continued approval of this indication may be contingent upon verification and description of clinical benefit at the final analysis of the KEYNOTE-811 study.

Key Points: 
  • Continued approval of this indication may be contingent upon verification and description of clinical benefit at the final analysis of the KEYNOTE-811 study.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • In the U.S., KEYTRUDA is also approved for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma, based on results from KEYNOTE-859.
  • Merck has an extensive clinical development program evaluating KEYTRUDA in gastrointestinal cancers and is continuing to study KEYTRUDA for multiple uses in gastric, hepatobiliary, esophageal and colorectal cancers.

Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity

Retrieved on: 
水曜日, 4月 17, 2024
PIC/S, Idiopathic pulmonary fibrosis, Adalimumab, Cancer, Social, NRDL, Certification, Trastuzumab, SCLC, Hand, Bevacizumab, Water, Carcinoma, Pollution, European, Environment, Rituximab, RMB, Patient, Mental health, ESG, Waste management, GHG, ALS, Marketing, Advertising, GMP, Recycling, Growth, Nursing

In 2023, Henlius was awarded by HR Asia "Best Companies To Work For In Asia" for two years in a row.

Key Points: 
  • In 2023, Henlius was awarded by HR Asia "Best Companies To Work For In Asia" for two years in a row.
  • Henlius strives to build a sustainable supply chain, continues optimizing supply chain operation mechanism, and strengthens supply chain risk management.
  • Henlius is committed to giving back to the community while striving for high-quality sustainable development.
  • The Company has established a sound four-tier ESG management structure and formulated an ESG management strategy model in line with the corporate development strategy.